MR45625 - Ranibizumab with Port Delivery System in nAMD - Sightspire

  • Research type

    Research Study

  • Full title

    A PHASE IIIb, MULTICENTER, SINGLE-ARM STUDY ASSESSING THE EFFECTIVENESS, SAFETY AND PATIENT REPORTED OUTCOMES OF A 36-WEEK REFILL EXCHANGE REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION - SIGHTSPIRE

  • IRAS ID

    1011768

  • Contact name

    Shady Mansour

  • Contact email

    welwyn.uk_ethics@roche.com

  • Sponsor organisation

    F. Hoffmann- La Roche AG

  • Clinicaltrials.gov Identifier

    NCT06847542

  • Research summary

    Neovascular age-related macular degeneration, also called wet age-related macular degeneration(AMD)is a form of advanced AMD that causes rapid&severe visual loss&remains a leading cause of visual impairment in older adults.
    Current treatment options include anti-vascular endothelial growth factor(VEGF) intravitreal(IVT) injections, which have been shown to stabilize&prevent vision loss in the majority of patients. However, a significant challenge with anti-VEGF therapy is the need for frequent&long-term administration due to the chronic nature of nAMD. Frequent IVT injections can place a substantial burden on individuals with nAMD, their caregivers,& the healthcare system. Therefore, there is a need for treatments that require less frequent dosing while still providing robust visual acuity(VA)benefits.
    The PDS implant is an intraocular refillable device that is surgically implanted through the pars plana to allow for a continuous delivery of ranibizumab into the vitreous. It is used in conjunction with a customized formulation of 100 mg/mL ranibizumab to precisely control the rate & duration of drug delivery & is refillable through the implant septum in situ.The PDS has been developed to address this unmet medical need by reducing the overall visit & treatment burden while achieving & maintaining optimal visual outcomes. The PDS with refills performed every 24 weeks has been approved in the United States for the treatment of nAMD since October 2021.
    The purpose of this study is to assess the effectiveness,safety&patient-reported outcomes(PROs) of the Port Delivery System with ranibizumab(PDS)with a 36-week refill cycle(Q36W)in patients with nAMD.
    Globally,250 Participants with nAMD will be recruited with 19 from the UK across 6 sites
    The study will last approximately 19 months for each participant however participants may continue to receive treatment until HA approval.
    The study is sponsored by F.Hoffmann- La Roche
    Research Summary; Version 1 19-May-2025

  • REC name

    West Midlands - Edgbaston Research Ethics Committee

  • REC reference

    25/WM/0164

  • Date of REC Opinion

    2 Oct 2025

  • REC opinion

    Further Information Favourable Opinion